Core Viewpoint - Guohai Securities initiates coverage on Zhonghui Biological-B (02627) with a "Buy" rating, predicting the company will achieve profitability by 2027, leading to a dual boost in performance and valuation known as the "Davis Double Play" [1] Group 1: Company Overview - Zhonghui Biological focuses on innovative vaccine upgrades and has entered the commercialization phase [1] - The company was established in 2015 and is dedicated to the research, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] Group 2: Product Pipeline - The company's core product, Huiliankangxin (Quadrivalent Influenza Virus Subunit Vaccine), has been launched and is expected to generate revenue of 260 million yuan in 2024, a 398% increase year-on-year [2] - The 23-valent pneumococcal polysaccharide vaccine and freeze-dried human rabies vaccine (human diploid cells) have completed Phase I clinical trials [1] Group 3: Market Potential - The domestic influenza vaccine market has significant growth potential, with split vaccines currently dominating market share [2] - The rabies vaccine market is substantial, with approximately 18 to 20 million people in China receiving rabies vaccinations annually [3] Group 4: Technological Advancements - The company has developed a leading core technology platform that supports both traditional vaccine upgrades and innovative vaccine development, with a pipeline of 11 vaccines under research [4] - The in-development human diploid cell rabies vaccine has shown good safety in Phase I trials and is designed for convenient administration [3]

Core Viewpoint - Guohai Securities initiates coverage on Zhonghui Biological-B (02627) with a "Buy" rating, predicting the company will achieve profitability by 2027, leading to a dual boost in performance and valuation known as the "Davis Double" [1] Group 1: Company Overview - Zhonghui Biological, established in 2015, focuses on the research, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - The company has launched its quadrivalent influenza virus subunit vaccine, with the 23-valent pneumococcal polysaccharide vaccine and freeze-dried human rabies vaccine having completed Phase I clinical trials [1] Group 2: Product Highlights - The Huierkangxin quadrivalent influenza virus subunit vaccine offers higher safety and good immune effects, targeting the high-end influenza vaccine market [1] - The domestic market for influenza vaccines has significant growth potential, with the quadrivalent subunit vaccine being the first and only of its kind in China, providing comprehensive protection and lower adverse reaction risks compared to split vaccines [1] - The product is expected to generate revenue of 260 million RMB in 2024, representing a 398% year-on-year increase, and is currently in a rapid growth phase [1] Group 3: Rabies Vaccine Development - The company is developing a human diploid cell rabies virus vaccine, which is based on WHO's gold standard technology, aiming to capture a high-quality rabies vaccine market worth billions [2] - With approximately 18 to 20 million people in China receiving rabies vaccinations annually, the company’s vaccine shows good safety in Phase I trials and offers convenient administration options [2] - The Phase III clinical trial for the rabies vaccine has been initiated as of December 2025 [2] Group 4: Research and Development Pipeline - The company has established a leading core technology platform that supports both traditional vaccine upgrades and innovative vaccine development, with a total of 11 vaccines in the research pipeline [2] - The focus is on unmet public health needs and high commercial potential indications, with the company actively developing additional vaccines to address market gaps [2]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Zhonghui Biotech-B (02627), which has risen over 20% to reach a new high of 54 HKD, marking a threefold increase from its IPO price of 12.9 HKD [1] - As of the report, the stock is up 22.65% at 53.6 HKD, with a trading volume of 43.85 million HKD and a total market capitalization exceeding 21 billion HKD [1] - The company announced that its quadrivalent influenza virus subunit vaccine, branded as Huiru Kangs, has been included in the preliminary review list of innovative drugs for national commercial health insurance, as published by the National Healthcare Security Administration on August 12 [1] Group 2 - The quadrivalent influenza virus subunit vaccine received New Drug Application (NDA) approval from the National Medical Products Administration in May 2023, making it the first and only quadrivalent influenza virus subunit vaccine approved in China until July 21, 2025 [1] - The vaccine is indicated for individuals aged three and above, with a specification of 15μg/0.5ml in terms of hemagglutinin concentration [1]